Yngvar Fløisand Selected Research

Hemolysis

1/2019

Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yngvar Fløisand Research Topics

Disease

9	Neoplasms (Cancer) 05/2024 - 03/2007
7	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2021 - 01/2010
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2024 - 10/2018
4	Leukemia 01/2023 - 05/2008
2	Lymphoma (Lymphomas) 05/2024 - 01/2018
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021 - 07/2019
2	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 01/2018
2	Infections 01/2019 - 09/2014
1	GATA2 Deficiency 01/2022
1	Crohn Disease (Crohn's Disease) 10/2021
1	Ulcerative Colitis 10/2021
1	Bronchiolitis Obliterans Syndrome 01/2021
1	Atherosclerosis 01/2021
1	Lymphoid Leukemia 01/2021
1	Atherosclerotic Plaque (Atheroma) 01/2021
1	Myeloid Leukemia (Leukemia, Myelocytic) 07/2019
1	Hemolysis 01/2019
1	Thromboinflammation 01/2019
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2018
1	Drug-Related Side Effects and Adverse Reactions 08/2015
1	Cytopenia 01/2014
1	Bronchiolitis Obliterans 08/2013
1	Osteoarthritis 01/2013
1	Pathologic Processes 02/2011
1	Hyperoxia 02/2011
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2010
1	Hematologic Diseases (Blood Diseases) 01/2010
1	Opportunistic Infections (Opportunistic Infection) 01/2010
1	T-Cell Prolymphocytic Leukemia (Leukemia, T Cell, Chronic) 03/2004
1	Herpes Zoster 03/2004
1	Chickenpox 03/2004

Drug/Important Bio-Agent (IBA)

3	SteroidsIBA 10/2021 - 01/2017
3	vedolizumabIBA 10/2021 - 01/2017
2	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2021
1	CytokinesIBA 05/2024
1	Chimeric Antigen ReceptorsIBA 05/2024
1	VaccinesIBA 01/2023
1	AntigensIBA 01/2023
1	LipidsIBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	Thomsen-Friedenreich antibodiesIBA 01/2021
1	GlobulinsIBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	Apolipoproteins E (ApoE)IBA 01/2021
1	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2021
1	DNA Glycosylases (DNA Glycosylase)IBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Peptides (Polypeptides)IBA 07/2019
1	Prothrombin (Factor II)IBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	HaptoglobinsIBA 01/2019
1	Heme (Haem)IBA 01/2019
1	HemopexinIBA 01/2019
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2018
1	Proteins (Proteins, Gene)FDA Link 10/2018
1	AntibodiesIBA 01/2018
1	Immunoglobulin G (IgG)IBA 01/2018
1	Immunoglobulin FragmentsIBA 01/2018
1	Rituximab (Mabthera)FDA Link 01/2018
1	Single-Chain AntibodiesIBA 01/2018
1	IntegrinsIBA 01/2017
1	Glutathione Transferase (Glutathione S-Transferase)IBA 08/2015
1	eltrombopag FDA Link 01/2014
1	Thrombopoietin ReceptorsIBA 01/2014
1	Carbon DioxideIBA 02/2011
1	Galectins (Galectin)IBA 02/2011
1	Galectin 1 (LGALS1)IBA 02/2011
1	Oxygen (Dioxygen)IBA 02/2011
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 05/2008
1	Toll-Like Receptor AgonistsIBA 10/2007
1	Alemtuzumab (Campath)FDA Link 03/2004
1	Antiviral Agents (Antivirals)IBA 03/2004

Therapy/Procedure

5	Hematopoietic Stem Cell Transplantation 01/2023 - 01/2010
4	Stem Cell Transplantation 01/2021 - 03/2007
3	Drug Therapy (Chemotherapy) 01/2023 - 05/2008
2	Induction Chemotherapy 01/2023 - 01/2023
2	Cell Transplantation 10/2021 - 01/2019
2	Transplantation 09/2014 - 01/2010
2	Therapeutics 01/2013 - 02/2011
1	Traction 12/2023
1	Intravenous Injections 01/2018
1	Lung Transplantation 08/2013